148 related articles for article (PubMed ID: 20460490)
1. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
2. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
3. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
Dempke WC; Heinemann V
Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
[TBL] [Abstract][Full Text] [Related]
4. Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.
Serrano C; Markman B; Tabernero J
Cancer J; 2010; 16(3):226-34. PubMed ID: 20526101
[TBL] [Abstract][Full Text] [Related]
5. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.
Jiang Y; Kimchi ET; Staveley-O'Carroll KF; Cheng H; Ajani JA
Cancer; 2009 Aug; 115(16):3609-17. PubMed ID: 19526592
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
Ohta M; Seto M; Ijichi H; Miyabayashi K; Kudo Y; Mohri D; Asaoka Y; Tada M; Tanaka Y; Ikenoue T; Kanai F; Kawabe T; Omata M
Gastroenterology; 2009 Jan; 136(1):206-16. PubMed ID: 18992247
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
8. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
9. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer.
Chen J; Huang XF; Katsifis A
J Cell Biochem; 2010 Dec; 111(5):1082-6. PubMed ID: 21053280
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Banck MS; Grothey A
Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849
[TBL] [Abstract][Full Text] [Related]
11. KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material.
Cavallini A; Valentini AM; Lippolis C; Campanella D; Guerra V; Caruso ML
Anticancer Res; 2010 Dec; 30(12):5251-6. PubMed ID: 21187522
[TBL] [Abstract][Full Text] [Related]
12. [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].
Bibeau F; Frugier H; Denouel A; Sabourin JC; Boissiere-Michot F
Bull Cancer; 2009 Dec; 96 Suppl():S15-22. PubMed ID: 20034866
[TBL] [Abstract][Full Text] [Related]
13. Predictive molecular classifiers in colorectal cancer.
Bohanes P; LaBonte MJ; Winder T; Lenz HJ
Semin Oncol; 2011 Aug; 38(4):576-87. PubMed ID: 21810517
[TBL] [Abstract][Full Text] [Related]
14. Incorporating new data on colorectal cancer into nursing practice.
Viale PH
Clin J Oncol Nurs; 2010 Feb; 14(1):92-100. PubMed ID: 20118032
[TBL] [Abstract][Full Text] [Related]
15. Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.
Zavodna K; Konecny M; Krivulcik T; Spanik S; Behulova R; Vizvaryova M; Weismanova E; Galbavy S; Kausitz J
Neoplasma; 2009; 56(3):275-8. PubMed ID: 19309232
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in the treatment of metastatic colorectal cancer.
Leong S; Messersmith WA; Tan AC; Eckhardt SG
Cancer J; 2010; 16(3):273-82. PubMed ID: 20526106
[TBL] [Abstract][Full Text] [Related]
17. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation.
Giampieri R; Scartozzi M; Del Prete M; Maccaroni E; Bittoni A; Faloppi L; Bianconi M; Cecchini L; Cascinu S
Crit Rev Oncol Hematol; 2013 Nov; 88(2):272-83. PubMed ID: 23806981
[TBL] [Abstract][Full Text] [Related]
18. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.
Malapelle U; Carlomagno C; de Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2014 Jan; 67(1):1-9. PubMed ID: 24022727
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment.
Fei BY; Wang XY; Fang XD
Tumour Biol; 2016 May; 37(5):5829-35. PubMed ID: 26581910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
